320 related articles for article (PubMed ID: 26655275)
1. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
2. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
3. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
4. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
Du B; Waxman DJ
Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
Doloff JC; Waxman DJ
BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
[TBL] [Abstract][Full Text] [Related]
6. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
7. TLR ligands in the local treatment of established intracerebral murine gliomas.
Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
10. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
11. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
Zhu S; Lv X; Zhang X; Li T; Zang G; Yang N; Wang X; Wu J; Chen W; Liu YJ; Chen J
Int J Cancer; 2019 Jun; 144(11):2867-2879. PubMed ID: 30565657
[TBL] [Abstract][Full Text] [Related]
12. Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Ouyang M; White EE; Ren H; Guo Q; Zhang I; Gao H; Yanyan S; Chen X; Weng Y; Da Fonseca A; Shah S; Manuel ER; Zhang L; Vonderfecht SL; Alizadeh D; Berlin JM; Badie B
PLoS One; 2016; 11(2):e0148139. PubMed ID: 26829221
[TBL] [Abstract][Full Text] [Related]
13. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
14. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
15. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance.
Tran AP; Ali Al-Radhawi M; Kareva I; Wu J; Waxman DJ; Sontag ED
Front Immunol; 2020; 11():1376. PubMed ID: 32695118
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
Doloff JC; Chen CS; Waxman DJ
Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
[TBL] [Abstract][Full Text] [Related]
17. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
19. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity.
Zhao D; Alizadeh D; Zhang L; Liu W; Farrukh O; Manuel E; Diamond DJ; Badie B
Clin Cancer Res; 2011 Feb; 17(4):771-82. PubMed ID: 21088258
[TBL] [Abstract][Full Text] [Related]
20. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
